These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7655003)

  • 1. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
    Saven A; Emanuele S; Kosty M; Koziol J; Ellison D; Piro L
    Blood; 1995 Sep; 86(5):1710-6. PubMed ID: 7655003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
    Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
    J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
    Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
    Ogura M; Morishima Y; Kobayashi Y; Uike N; Sugai S; Chou T; Kasai M; Miura I; Murayama T; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Tobinai K;
    Int J Hematol; 2004 Oct; 80(3):267-77. PubMed ID: 15540903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas.
    Rummel MJ; Chow KU; Jäger E; Leimer L; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
    Leuk Lymphoma; 1999 Sep; 35(1-2):129-38. PubMed ID: 10512170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
    Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
    Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
    Liliemark J; Martinsson U; Cavallin-Ståhl E; Svedmyr E; Porwit A; Strömberg M; Juliusson G
    Leuk Lymphoma; 1998 Aug; 30(5-6):573-81. PubMed ID: 9711919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
    Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
    Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
    Hoffman M; Tallman MS; Hakimian D; Janson D; Hogan D; Variakogis D; Kuzel T; Gordon LI; Rai K
    J Clin Oncol; 1994 Apr; 12(4):788-92. PubMed ID: 7908690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphomas.
    Canfield VA; Vose J; Guiney P; Bennett B; Nichols C
    Leuk Lymphoma; 1997 Jan; 24(3-4):335-9. PubMed ID: 9156663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma.
    Betticher DC; Zucca E; von Rohr A; Egger T; Radford JA; Ambrosetti A; Bürki K; Rufener B; Schmitz SF; Cerny T
    Ann Oncol; 1996 Oct; 7(8):793-9. PubMed ID: 8922192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse.
    Rummel MJ; Chow KU; Jäger E; Hossfeld DK; Bergmann L; Peters HD; Hansmann ML; Meyer A; Hoelzer D; Mitrou PS
    Ann Oncol; 1999 Jan; 10(1):115-7. PubMed ID: 10076731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
    Róbak T; Gora-Tybor J; Krykowski E; Walewski JA; Borawska A; Pluźańska A; Potemski P; Hellmann A; Zaucha JM; Konopka L; Ceglarek B; Durźyński T; Sikorska A; Michalak K; Urasiński J; Opalińska J; Dmoszyńska A; Adamczyk-Cioch MB; Kuratowska Z; Dwilewicz-Trojaczek J; Boguradzki P; Deren M; Maj S; Grieb P
    Leuk Lymphoma; 1997 Jun; 26(1-2):99-105. PubMed ID: 9250793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma.
    Liliemark J; Porwit A; Juliusson G
    Leuk Lymphoma; 1997 Apr; 25(3-4):313-8. PubMed ID: 9168441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
    Blum KA; Johnson JL; Niedzwiecki D; Piro LD; Saven A; Peterson BA; Byrd JC; Cheson BD;
    Cancer; 2006 Dec; 107(12):2817-25. PubMed ID: 17120198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
    Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
    Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma.
    Saven A; Lee T; Kosty M; Piro L
    J Clin Oncol; 1996 Jul; 14(7):2139-44. PubMed ID: 8683247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.